Given the results of KEYNOTE-062 presented at ASCO 2019, how will you utilize immunotherapy in gastric cancer?
KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compared to platinum based chemotherapy. Pembro is currently approved as third line in PD-L1+ patients. In light of this data, would you consider upfront IO for patients with high CPS?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
Interpretation of Keynote-062 study results is complicated. The primary endpoint was non-inferiority of pembrolizumab alone versus chemotherapy for first line therapy in patients with CPS>1. This primary endpoint was met, however the PFS curves are quite revealing in that chemotherapy arm does much ...
Join for free or sign in to see the full answer